Givaudan SA CEO Giles Andrier told investors that potential tariffs levied by the Trump Administration should not impact sales of its finished products to customers, as “we actually make in the US all of the things that we sell in the US.”
Givaudan Unfazed By Potential Tariffs On Finished Goods: US-Sold Products Also Made in US – CEO
Givaudan CEO Giles Andrier told analysts during the Swiss firm’s 2024 sales presentation that strong sales in Q4 were not impacted by a pre-buying of products and ingredients late in the year, as experienced by other companies, in anticipation of potential new tariffs imposed by the Trump administration.
More from Policy & Regulation
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.
• By
Cosmetic companies should conduct audits to identify products that will be required to disclose fragrance allergens and begin the work of adjusting labels, particularly for smaller packaging, says a director at Registrar Corp., during a 12 March webinar on MoCRA and labeling.
More from HBW Insight
• By
Kim Kardashian lifestyle company SKIMS buys back rights to SKKN by Kim from Coty, Inc., which had purchased a 20% interest in the brand in 2020 for $200m. Separately, NYX Professional Makeup partners with Warner Bros. to launch the “A Minecraft Movie” collection.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
US FDA Commissioner nominee Martin Makary is being embraced by industry, and Senate Democrats, as a more traditional pick than other Trump Administration nominees, but the Make America Healthy Again agenda still is clearly coming to the agency.